Last update Dec. 20, 2021
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Lixisenatide in other languages or writings:
Lixisenatide belongs to these groups or families:
Main tradenames from several countries containing Lixisenatide in its composition:
|Tmax||1 - 3.5||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Exenatide is an incretin hormone analog used in the treatment of type 2 diabetes.
Subcutaneous administration every 24 hours.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (high molecular weight, large volume of distribution and and short half life) make it very unlikely that significant amounts will pass into breast milk. (Serrano 2014)
Due to its protein nature, it deteriorates in the gastrointestinal tract, not being absorbed (Serrano 2014). This low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.
Diet, exercise, and breastfeeding improve blood sugar levels.